Yehuda Z. Cohen

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study

Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation

Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117

Relationship between intact HIV-1 proviruses in circulating CD4 ⁺ T cells and rebound viruses emerging during treatment interruption

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA